Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

[1]  C. Craddock,et al.  Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Maris,et al.  Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors , 2006 .

[4]  C. Craddock,et al.  Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. , 2007, Blood.

[5]  F. Appelbaum,et al.  Hematopoietic-cell transplantation at 50. , 2007, The New England journal of medicine.

[6]  P. Greenberg,et al.  Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. , 2007, Blood.

[7]  C. Huber,et al.  Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. , 2008, Journal of immunological methods.

[8]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[9]  H. Tanke,et al.  Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. , 2009, Blood.

[10]  F. Appelbaum.  Optimising the conditioning regimen for acute myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[11]  H. Kantarjian,et al.  Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia , 2009, Cancer.

[12]  J. Vose,et al.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  F. J. Gonzalez,et al.  Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. , 2010, Blood.

[14]  N. Kröger,et al.  5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis , 2010, Bone Marrow Transplantation.

[15]  W. Shannon,et al.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.

[16]  P. Vyas,et al.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. , 2010, Blood.

[17]  P. Vyas,et al.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia , 2010, Haematologica.

[18]  Krishna Komanduri,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[19]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Borkhardt,et al.  Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. , 2011, Blood.

[21]  C. Craddock,et al.  Unrelated donor peripheral blood stem cell transplants incorporating pre‐transplant in‐vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft‐versus‐host disease , 2011, British journal of haematology.

[22]  K. Rezvani,et al.  Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy , 2012, Cancer Immunology, Immunotherapy.

[23]  A. Kiani,et al.  Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse , 2011, Haematologica.

[24]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[25]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[26]  P. Chevallier,et al.  Azacitidine after allo-SCT: the good without the bad? , 2012, Blood.

[27]  N. Kröger,et al.  Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation , 2013, Leukemia.

[28]  N. Kröger,et al.  Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation , 2013, Leukemia.

[29]  G. Mufti,et al.  Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .